Genetics of Prostate Carcinoma.

Area of Science:

• Oncology
• Genetics
• Animal Models

Background:

• Prostate carcinoma (PCa) is a leading cause of cancer death in men, with excellent outcomes for localized disease but poor prognosis for castrate-resistant and metastatic PCa.
• Despite advances, significant challenges remain in treating advanced PCa, highlighting the need for better understanding of its genetic underpinnings.

Purpose of the Study:

• To review current approaches in PCa diagnostics, pathology, treatment, and genetics.
• To emphasize the critical need for improved genetically engineered mouse models that accurately reflect PCa's molecular subtypes and metastatic potential.

Main Methods:

• Review of current literature on prostate carcinoma diagnostics, pathology, treatment, and genetics.
• Analysis of large-scale genomic studies in PCa.
• Discussion on the requirements for developing advanced, genetically engineered mouse models.

Main Results:

• Large-scale genomic studies have identified numerous genetic alterations in PCa, requiring validation within specific molecular subtypes.
• Existing animal models often fail to replicate key features of metastatic PCa, including bone metastasis and neuroendocrine or sarcomatoid subtypes.
• There is a critical need for models that mimic androgen deprivation, relapse, and androgen independence to better study metastatic castrate-resistant prostate cancer.

Conclusions:

• While localized prostate carcinoma treatment yields excellent results, advanced stages like castrate-resistant and metastatic PCa have a poor prognosis.
• Genetically engineered mouse models are essential for elucidating genetic changes in PCa and developing more effective treatments for resistant forms.